Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Huse, Kanutte ^a,b   Bakkebø, Maren ^a,b   Wälchli, Sébastien ^a   Oksvold, Morten P ^a,b   Hilden, Vera I ^a,b   Forfang, Lise ^a,b   Bredahl, May L ^a,b   Liestøl, Knut ^b   Alizadeh, Ash A ^c   Smeland, Erlend B ^a,b   Myklebust, June H ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; DNA; MESSENGER RNA; OSTEOGENIC PROTEIN 1; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MOLECULAR SEQUENCE DATA; NUCLEIC ACID SYNTHESIS INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84867003141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046117     Document Type: Article

References (55)

1. ten Dijke P, Korchynskyi O, Valdimarsdottir G, Goumans MJ, (2003) Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 211: 105-113.
2. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, et al. (2011) Bone Morphogenetic Proteins: A critical review. Cell Signal 23: 609-620.
3. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, et al. (1999) Bone Morphogenetic Proteins Regulate the Developmental Program of Human Hematopoietic Stem Cells. J Exp Med 189: 1139-1148.
4. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, et al. (2006) BMP-6 inhibits human bone marrow B lymphopoiesis- Upregulation of Id1 and Id3. Exp Hematol 34: 72-81.
5. Cejalvo T, Sacedón R, Hernández-López C, Diez B, Gutierrez-Frías C, et al. (2007) Bone morphogenetic protein-2/4 signalling pathwaycomponents are expressed in the human thymus and inhibit early T-cell development. Immunology 121: 94-104.
6. Varas A, Martinez VG, Hernández-López C, Hidalgo L, Entrena A, et al. (2009) Role of BMP signalling in peripheral CD4+ T cell proliferation. Inmunología 28: 125-130.
7. Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, et al. (2005) BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol 6: 9.
8. Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, et al. (2011) Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7. Eur J Immunol 41: 3135-3145.
9. Tsalavos S, Segklia K, Passa O, Petryk A, O'Connor MB, et al. (2011) Involvement of Twisted Gastrulation in T Cell-Independent Plasma Cell Production. J Immunol 186: 6860-6870.
10. Seoane J, (2006) Escaping from the TGFβ anti-proliferative control. Carcinogenesis 27: 2148-2156.
11. Levy L, Hill CS, (2002) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58.
12. Kim IY, Kim SJ, (2006) Role of bone morphogenetic proteins in transitional cell carcinoma cells. Cancer Lett 241: 118-123.
13. Thawani JP, Wang AC, Than KD, Lin CY, Marca FL, et al. (2010) Bone Morphogenetic Proteins and Cancer: Review of the Literature. Neurosurgery 66: 233-246.
14. Kodach LL, Wiercinska E, de Miranda NFCC, Bleuming SA, Musler AR, et al. (2008) The Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers. Gastroenterology 134: 1332-1341.
15. Daibata M, Nemoto Y, Bandobashi K, Kotani N, Kuroda M, et al. (2007) Promoter Hypermethylation of the Bone Morphogenetic Protein-6 Gene in Malignant Lymphoma. Clin Cancer Res 13: 3528-3535.
16. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390.
17. Choi YS, (1997) Differentiation and Apoptosis of Human Germinal Center B-Lymphocytes. Immunol Res 16: 161-174.
18. Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, et al. (2003) Decreased Expression of Bone Morphogenetic Protein (BMP) Receptor Type II Correlates with Insensitivity to BMP-6 in Human Renal Cell Carcinoma Cells. Clin Cancer Res 9: 6046-6051.
19. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, et al. (2004) Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23: 7651-7659.
20. Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM, et al. (2004) Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Res 64: 7355-7360.
21. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
22. Sieber C, Kopf J, Hiepen C, Knaus P, (2009) Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20: 343-355.
23. Hsu MY, Rovinsky S, Lai CY, Qasem S, Liu X, et al. (2008) Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest 88: 842-855.
24. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, et al. (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28: 3866-3879.
25. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. N Engl J Med 346: 1937-1947.
26. Grčević D, Kušec R, Kovačić N, Lukić A, Lukić IK, et al. (2010) Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res 34: 742-751.
27. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, et al. (2004) Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23: 3024-3032.
28. Hjertner O, Hjorth-Hansen H, Börset M, Seidel C, Waage A, et al. (2001) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97: 516-522.
29. Kawamura C, Kizaki M, Ikeda Y, (2002) Bone Morphogenetic Protein (BMP)-2 Induces Apoptosis in Human Myeloma Cells. Leuk Lymphoma 43: 635-639.
30. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, et al. (1997) Growth Regulation of Human Prostate Cancer Cells by Bone Morphogenetic Protein-2. Cancer Res 57: 5022-5027.
31. Langenfeld EM, Kong Y, Langenfeld J, (2005) Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 25: 685-692.
32. Chen G, Ghosh P, Osawa H, Sasaki CY, Rezanka L, et al. (2007) Resistance to TGF-β1 correlates with aberrant expression of TGF-β receptor II in human B-cell lymphoma cell lines. Blood 109: 5301-5307.
33. Kim SJ, Letterio J, (2003) Transforming growth factor-β signaling in normal and malignant hematopoiesis. Leukemia 17: 1731-1737.
34. Pangas SA, Li X, Umans L, Zwijsen A, Huylebroeck D, et al. (2008) Conditional Deletion of Smad1 and Smad5 in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice. Mol Cell Biol 28: 248-257.
35. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, et al. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary medistinal and diffuse large B cell lymphomas. J Pathol 207: 243-249.
36. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, et al. (2008) MicroRNA signatures characterize diffuse large B-cell lymhpomas and follicular lymphomas. Br J Haematol 142: 732-744.
37. Rai D, Kim SW, McKeller MR, Dahia PLM, Aguiar RCT, (2010) Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis. Proc Natl Acad Sci U S A 107: 3111-3116.
38. Rai D, Karanti S, Jung I, Dahia PLM, Aguiar RCT, (2008) Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 181: 8-15.
39. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, et al. (1999) Smad6 Suppresses TGF-β-Induced Growth Inhibition in COLO-357 Pancreatic Cancer Cells and Is Overexpressed in Pancreatic Cancer. Biochem Biophys Res Commun 255: 268-273.
40. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, et al. (1999) The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 23: 5363-5372.
41. Jeon HS, Dracheva T, Yang SH, Meerzaman D, Fukuoka J, et al. (2008) SMAD6 Contributes to Patient Survival in Non-Small Cell Lung Cancer and Its Knockdown Reestablishes TGF-β Homeostasis in Lung Cancer Cells. Cancer Res 68: 9686-9692.
42. Kim YH, Lee HS, Lee HJ, Hur K, Kim WH, et al. (2004) Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol 15: 574-580.
43. Zhang S, Fei T, Zhang L, Zhang R, Chen F, et al. (2007) Smad7 Antagonizes Transforming Growth Factor β Signaling in the Nucleus by Interfering with Functional Smad-DNA Complex Formation. Mol Cell Biol 27: 4488-4499.
44. Bernabeu C, Lopez-Novoa JM, Quintanilla M, (2009) The emerging role of TGF-β superfamily coreceptors in cancer. Biochim Biophys Acta 1792: 954-973.
45. Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, et al. (2011) Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia 26: 1073-1080.
46. Patil S, Wildey GM, Brown TL, Choy L, Derynck R, et al. (2000) Smad7 Is Induced by CD40 and Protects WEHI 231 B-lymphocytes from Transforming Growth Factor-β-induced Growth Inhibition and Apoptosis. J Biol Chem 275: 38363-38370.
47. Wu MY, Hill CS, (2009) TGF-β Superfamily Signaling in Embryonic Development and Homeostasis. Dev Cell 16: 329-343.
48. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J, (2007) Balancing BMP Signaling through Integrated Inputs into the Smad1 Linker. Mol Cell 25: 441-454.
49. Bakkebø M, Huse K, Hilden V, Smeland E, Oksvold M, (2010) TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol 11: 57.
50. Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aashein HC, et al. (2005) PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 206: 312-319.
51. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, et al. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107: 12747-12754.
52. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, et al. (2002) IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J Clin Invest 109: 931-937.
53. Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, et al. (2009) A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood 114: 3158-3166.
54. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.
55. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.